ClinicalTrials.gov
ClinicalTrials.gov Menu

Physiological, Behavioral and Subjective Effects of Drugs (GHB)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00058955
Recruitment Status : Completed
First Posted : April 16, 2003
Last Update Posted : September 10, 2008
Sponsor:
Collaborator:
Johns Hopkins University
Information provided by:
Orphan Medical

Brief Summary:
The purpose of this study is to learn more about the effects of gamma-hydroxybutyric acid (GHB) by comparing its physiological, behavioral and subjective effects with those of several other drugs.

Condition or disease Intervention/treatment Phase
Sedative Abuse Drug: sodium oxybate, triazolam and pentobarbital Phase 1

Detailed Description:

The purpose of this study is to learn more about the effects of gamma-hydroxybutyric acid by comparing its physiological, behavioral and subjective effects with those of several other drugs.

This trial will be conducted as a double-blind, double-dummy, placebo-controlled, counter-balanced (Latin-square design) crossover study in volunteers with histories of sedative abuse. Volunteers will be recruited through advertising and word-of-mouth.

Volunteers will reside on our residential research unit for the duration of the study and participate in a maximum of 16 experimental sessions. Sessions will be conducted five days a week (Monday through Friday). The primary subjective and behavioral measures will be taken before drug administration and at 0.5, 1, 2, 3, 4, 6, 8, 12 and 24 hours after drug administration.


Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Allocation: Non-Randomized
Intervention Model: Crossover Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: Physiological, Behavioral and Subjective Effects of Drugs (GHB)
Study Start Date : August 2003
Study Completion Date : March 2005

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Club Drugs
U.S. FDA Resources

Arm Intervention/treatment
Experimental: 1
Sodium oxybate
Drug: sodium oxybate, triazolam and pentobarbital
sodium oxybate, triazolam and pentobarbital
Other Name: Xyrem
Active Comparator: 2
triazolam
Drug: sodium oxybate, triazolam and pentobarbital
sodium oxybate, triazolam and pentobarbital
Other Name: Xyrem
Active Comparator: 3
pentobarbital
Drug: sodium oxybate, triazolam and pentobarbital
sodium oxybate, triazolam and pentobarbital
Other Name: Xyrem
Placebo Comparator: 4
Placebo
Drug: sodium oxybate, triazolam and pentobarbital
sodium oxybate, triazolam and pentobarbital
Other Name: Xyrem



Primary Outcome Measures :
  1. Pharmacokinetics


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

INCLUSION CRITERIA

  • are ages 18-50 years
  • have histories of sedative (e.g., GHB, alcohol, benzodiazepine or barbiturate) abuse
  • are within 20% of their ideal body weight
  • are healthy as determined by screening for medical problems via a personal interview, a medical questionnaire, a physical examination, and routine medical blood and urinalysis laboratory tests
  • are not currently pregnant or breast-feeding, if female
  • have signed and dated an informed consent form prior to beginning the study
  • are willing and able to participate

EXCLUSION CRITERIA

  • have a history or current serious medical or psychiatric conditions, including (but not limited to): heart condition, lung disease, diabetes, seizure disorders, significant gastrointestinal disturbances, narrow angle glaucoma, ulcers, sleep apnea, schizophrenia, personality disorder, bipolar disorder, paranoia, multiple personality disorder
  • have hypersensitivity/allergy or other contraindications to sedatives or stimulants
  • are physically dependent on alcohol or other drugs, excluding nicotine and caffeine
  • are females who are pregnant or are breast feeding
  • are females who become pregnant during the study as evaluated using periodic pregnancy tests

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00058955


Locations
United States, Maryland
Johns Hopkins University School of Medicine/Bayview Medical Center
Baltimore, Maryland, United States, 21224
Sponsors and Collaborators
Orphan Medical
Johns Hopkins University
Investigators
Principal Investigator: Roland Griffiths, PhD Johns Hopkins University

Publications:
Responsible Party: Senior Director of Clinical Development, Jazz Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier: NCT00058955     History of Changes
Other Study ID Numbers: OMC-SXB-25
BPR00-09-27-02
First Posted: April 16, 2003    Key Record Dates
Last Update Posted: September 10, 2008
Last Verified: September 2008

Keywords provided by Orphan Medical:
ghb
Xyrem
triazolam
pentobarbital
sedative
abuse

Additional relevant MeSH terms:
Sodium Oxybate
Triazolam
Pentobarbital
Adjuvants, Anesthesia
Anesthetics, Intravenous
Anesthetics, General
Anesthetics
Central Nervous System Depressants
Physiological Effects of Drugs
Anti-Anxiety Agents
Tranquilizing Agents
Psychotropic Drugs
GABA Modulators
GABA Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Hypnotics and Sedatives